Author

C. Busonero

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

F. Acconcia· 3 shared S. Leone· 3 shared C. Klemm· 1 shared F. Bianchi· 1 shared M. Cipolletti· 1 shared S. Bartoloni· 1 shared

Activity by Year

2017-2020 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Acconcia

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Real-time measurement of E2:ERα transcriptional activity in living cells.

M. Cipolletti, S. Leone, S. Bartoloni, C. Busonero, F. Acconcia

This study develops stable cell lines to monitor real-time ERα transcriptional activity in response to E2 and identifies biphasic dynamics and dose-dependent effects.

bioRxiv · Jan 11, 2020Physiology

In silico screening for ERα downmodulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells

C. Busonero, S. Leone, F. Bianchi, F. Acconcia

The paper identifies thioridazine as an anti-proliferative agent effective against ERα-expressing breast cancer cells resistant to tamoxifen.

bioRxiv · May 18, 2018Cancer Biology

A Functional Drug Re-Purposing Screening Identifies Carfilzomib As A Drug Preventing 17β-Estradiol: ERα Signaling And Cell Proliferation In Breast Cancer Cells

C. Busonero, S. Leone, C. Klemm, F. Acconcia

This study identifies carfilzomib as a drug that prevents 17β-estradiol:ERα signaling and inhibits cell proliferation in breast cancer cells, showing efficacy in tamoxifen-resistant models.

bioRxiv · May 3, 2017Cancer Biology